Has Jessica Hawley, MD received payments from drug or device companies?

Yes. Drug and device makers reported $4,120 in general payments to Jessica Hawley, MD across 13 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jessica Hawley, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jessica Hawley, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jessica Hawley, MD

Medical Oncology · Seattle, WANPI 1659663979

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $3,153 of the $4,120 with a category attached, or 76.5%. Daiichi Sankyo Inc. accounts for 76.5% of it on its own, with 7 other manufacturers making up the rest.

$4,120in general payments, 2019–2025

Across 13 payments — averaging $316.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Daiichi Sankyo Inc.$3K
Sanofi$335
GSK$164
Amgen$162
Seagen Inc.$152
E.r. Squibb & Sons, L.L.C.$79
plus $76 from 2 others

$2,674,005in research payments, 2019–2025

Across 56 payments — averaging $47,750 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Bristol Myers Squibb$769K
Amgen$583K
Astrazeneca UK Limited$427K
Macrogenics, Inc.$385K
E.r. Squibb & Sons, L.L.C.$248K
Janssen Research & Development, LLC$235K
plus $27K from 1 others

What the payments were for

Consulting fees$3,15377%
Travel & lodging$2085%
Food & beverage$76018%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Daiichi Sankyo Inc.	2	$3,153
Sanofi	3	$335
GSK	2	$164
Amgen	2	$162
Seagen Inc.	1	$152
E.r. Squibb & Sons, L.L.C.	1	$79
Dendreon Pharmaceuticals LLC	1	$45
Exelixis Inc.	1	$30

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

NO PRODUCT DISCUSSED$287

How this compares

$4,120 in reported general payments places this provider in the 60th percentile of 162 medical oncology providers in Washington.

See all medical oncology providers in Washington →

Medicare billing

Part B allowed, 2024

$43,781

Medicare patients

137

Services billed

483

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
XtandiEnzalutamide	50	$708,549
NubeqaDarolutamide	27	$377,481
Abiraterone Acetate	109	$30,490
Prednisone	81	$308
Tamsulosin Hcl	14	$261

Paid to pharmacies, not to this prescriber.

Other medical oncology in Seattle

Bart ScottSeattle$1.3M
Petros GrivasSeattle$628K
Vijayakrishna GadiSeattle$573K
Evan YuSeattle$296K
Siddhartha DevarakondaSeattle$215K
David MaloneySeattle$150K
Gary LymanSeattle$130K
Rafic FarahSeattle$114K
Laura ChowSeattle$114K
Shailender BhatiaSeattle$107K

See the full list for Washington →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →